According to Zacks, “Lilly’s fourth-quarter results were mixed with earnings missing estimates but revenues beating the same. Earnings jumped 22% year over year backed by strong diabetes sales. In 2017, while new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to see higher revenues, Lilly expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. Although the stock’s decline was sharper than the large cap pharma industry in 2016, it has done well in 2017. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets.”
A number of other equities analysts have also weighed in on LLY. Goldman Sachs Group, Inc. (The) upgraded shares of Eli Lilly and Company from a buy rating to a conviction-buy rating in a research report on Thursday, December 15th. Morgan Stanley set a $73.00 target price on shares of Eli Lilly and Company and gave the company a hold rating in a report on Thursday, November 24th. Credit Suisse Group reiterated a focus list rating and set a $87.00 price target on shares of Eli Lilly and Company in a research note on Monday, December 19th. Vetr cut shares of Eli Lilly and Company from a hold rating to a sell rating and set a $74.30 price target for the company. in a report on Tuesday, January 31st. Finally, Leerink Swann restated an outperform rating and issued a $92.00 price objective (down previously from $102.00) on shares of Eli Lilly and Company in a research report on Saturday, November 26th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $86.41.
Shares of Eli Lilly and Company (NYSE:LLY) opened at 78.81 on Wednesday. The stock has a market cap of $84.49 billion, a price-to-earnings ratio of 30.57 and a beta of 0.30. The stock’s 50 day moving average is $76.19 and its 200-day moving average is $76.63. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $83.79.
Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, January 31st. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.98 by $0.03. The company earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. Eli Lilly and Company had a net margin of 12.90% and a return on equity of 24.74%. The business’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.78 EPS. Equities analysts anticipate that Eli Lilly and Company will post $4.10 EPS for the current fiscal year.
This piece of content was first published by sleekmoney and is owned by of sleekmoney. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at http://sleekmoney.com/zacks-investment-research-lowers-eli-lilly-and-company-lly-to-hold/1662302.html.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 10th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date is Monday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $0.51. Eli Lilly and Company’s dividend payout ratio is currently 80.62%.
In other news, SVP Alfonso G. Zulueta sold 15,000 shares of the business’s stock in a transaction on Monday, February 6th. The shares were sold at an average price of $77.66, for a total transaction of $1,164,900.00. Following the completion of the sale, the senior vice president now directly owns 45,583 shares of the company’s stock, valued at approximately $3,539,975.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $77.35, for a total transaction of $17,017,000.00. Following the sale, the insider now directly owns 125,359,047 shares of the company’s stock, valued at $9,696,522,285.45. The disclosure for this sale can be found here. Insiders have sold 470,497 shares of company stock worth $35,358,665 in the last 90 days. Insiders own 0.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Tradewinds Capital Management LLC raised its position in Eli Lilly and Company by 22.3% in the third quarter. Tradewinds Capital Management LLC now owns 1,345 shares of the company’s stock valued at $108,000 after buying an additional 245 shares in the last quarter. Integrated Wealth Management increased its stake in Eli Lilly and Company by 3.7% in the third quarter. Integrated Wealth Management now owns 1,389 shares of the company’s stock worth $112,000 after buying an additional 50 shares during the period. Financial Architects Inc increased its stake in Eli Lilly and Company by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the period. Tarbox Group Inc. raised its position in Eli Lilly and Company by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock valued at $124,000 after buying an additional 11 shares during the last quarter. Finally, Penserra Capital Management LLC raised its position in Eli Lilly and Company by 100.0% in the third quarter. Penserra Capital Management LLC now owns 1,584 shares of the company’s stock valued at $127,000 after buying an additional 792 shares during the last quarter. Hedge funds and other institutional investors own 75.15% of the company’s stock.
About Eli Lilly and Company
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zacks-investment-research-lowers-eli-lilly-and-company-lly-to-hold/1662302.html
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.